Get the Stockscreener App
88.43
0.52%
-0.15
Transmedics Group Inc stock is traded at $88.43, with a volume of 258.53K.
It is down -0.52% in the last 24 hours and up +19.11% over the past month.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
See More
Previous Close:
$88.58
Open:
$87.25
24h Volume:
258.53K
Relative Volume:
0.23
Market Cap:
$3.07B
Revenue:
$635.89M
Net Income/Loss:
$171.92M
P/E Ratio:
20.30
EPS:
4.357
Net Cash Flow:
$151.36M
1W Performance:
-0.33%
1M Performance:
+19.11%
6M Performance:
-34.15%
1Y Performance:
-30.91%
1-Day Range:
$86.80
$88.60
1-Week Range:
$85.81
$90.09
52-Week Range:
$60.10
$156.00
Transmedics Group Inc Stock (TMDX) Company Profile
Name
Transmedics Group Inc
Sector
Industry
Phone
(978) 552-0900
Address
200 MINUTEMAN ROAD, ANDOVER, MA
Compare TMDX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TMDX
Transmedics Group Inc
|
88.43 | 3.07B | 635.89M | 171.92M | 151.36M | 4.357 |
ABT
Abbott Laboratories
|
110.14 | 192.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
332.14 | 130.11B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
90.67 | 116.83B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.52 | 75.11B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.79 | 52.80B | 6.30B | 1.07B | 1.09B | 1.8406 |
Transmedics Group Inc Stock (TMDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-23-25 | Upgrade | Needham | Hold → Buy |
| Oct-13-25 | Initiated | Jefferies | Buy |
| Sep-16-25 | Initiated | Evercore ISI | Outperform |
| Sep-04-25 | Initiated | Stifel | Hold |
| Dec-17-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-22-24 | Downgrade | Needham | Buy → Hold |
| Oct-29-24 | Reiterated | Needham | Buy |
| Oct-29-24 | Reiterated | Oppenheimer | Outperform |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Aug-21-24 | Initiated | Needham | Buy |
| Jun-06-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-24 | Initiated | Stephens | Overweight |
| Mar-28-24 | Initiated | Piper Sandler | Overweight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Aug-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-08-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-07-20 | Initiated | Oppenheimer | Outperform |
| May-28-19 | Initiated | Canaccord Genuity | Buy |
| May-28-19 | Initiated | Cowen | Outperform |
| May-28-19 | Initiated | JP Morgan | Overweight |
| May-28-19 | Initiated | Morgan Stanley | Equal-Weight |
View All
Transmedics Group Inc Stock (TMDX) Latest News
TransMedics Group, Inc. $TMDX Shares Sold by Royal Bank of Canada - marketbeat.com
Law firm investigates TransMedics officers for possible shareholder duty breaches - Pluang
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Recommendation of "Hold" from Brokerages - marketbeat.com
ETFs Investing in TransMedics Group, Inc. Stocks - TradingView
ChronicCareIQ Appoints Tom Visotsky as Chief Revenue Officer - AOL.com
Transmedics Group Stock Price Forecast. Should You Buy TMDX? - StockInvest.us
TransMedics (TMDX) Q2 2026 Earnings Call Transcript - AOL.com
symbol__ Stock Quote Price and Forecast - CNN
TransMedics Group, Inc. Investor News: Rosen Law Firm - GlobeNewswire
(TMDX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Wasatch Advisors LP Has $20.49 Million Stock Position in TransMedics Group, Inc. $TMDX - marketbeat.com
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc.TMDX - Sahm
TMDX: Strong growth, new kidney program, and global expansion set stage for multi-billion revenue - TradingView
TransMedics Group, Inc. (TMDX) Stock Analysis: Healthcare Innovations with a 15.99% Upside Potential - DirectorsTalk Interviews
Why TransMedics Stock Is Sinking Today - AOL.com
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Microvast Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX - GlobeNewswire Inc.
Q4 2025 Transmedics Group Inc Earnings Call Transcript - GuruFocus
Q1 2026 Transmedics Group Inc Earnings Call Transcript - GuruFocus
Transmedics Group Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
TransMedics Group Inc (TMDX) Stock Up 4.9% and Still Undervalued -- GF Score: 70/100 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
TransMedics: Margins Down, Concentration Up, Trials Delayed - Seeking Alpha
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc.TMDX - Sahm
Q2 2026 Transmedics Group Inc Earnings Call Transcript - GuruFocus
TransMedics Group (NASDAQ:TMDX) Price Target Lowered to $77.00 at UBS Group - MarketBeat
Why TransMedics Group (TMDX) Stock Is Down Today - Quiver Quantitative
TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract - Yahoo Finance
TransMedics Group (NASDAQ:TMDX) Shares Gap Down on Disappointing Earnings - MarketBeat
TransMedics Group, Inc. Stock 12‑Month Price Target Cut to $97.3, Implies 20% Upside - TradingView
TransMedics Group, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:TMDX) 2026-08-05 - Seeking Alpha
TransMedics Group (TMDX) Stock Looks Cheap On Earnings But Full After 171% Gain - Yahoo Finance
TransMedics Group Inc (TMDX) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
TransMedics Group Q2 Earnings Call Highlights - MarketBeat
Do TransMedics’ (TMDX) New Equity Grants And UBS Coverage Reveal A Shifting Growth Playbook? - webull.com
TransMedics Group (NASDAQ:TMDX) Posts Earnings Results, Misses Expectations By $0.06 EPS - MarketBeat
TransMedics (TMDX) Reports Q2 Earnings: What Key Metrics Have to Say - finance.yahoo.com
Earnings call transcript: TransMedics Q2 2026 revenue rises, but EPS misses - Investing.com
Is TransMedics Group Inc (TMDX) Undervalued After Q2 Earnings Mi - GuruFocus
TransMedics Group Q2 Adjusted Net Income Falls, Revenue Rises - marketscreener.com
TransMedics (TMDX) Q2 Earnings Lag Estimates - Yahoo Finance
Transmedics Group Inc reports results for the quarter ended June 30Earnings Summary - TradingView
TransMedics Group (TMDX) Stock Rises on Q2 2026 Earnings - Quiver Quantitative
Earnings Flash (TMDX) TransMedics Group, Inc. Reports Q2 Revenue $189.9M, vs. FactSet Est of $184.0M - marketscreener.com
Earnings Flash (TMDX) TransMedics Group, Inc. Posts Q2 Adjusted EPS $0.44 per Share, vs. FactSet Est of $0.47 - marketscreener.com
TransMedics Group, Inc. (TMDX) Q2 FY2026 earnings call transcript - Yahoo Finance
TransMedics Group, Inc. Q2 2026: Revenue $189.9M, EPS $0.41— 10-Q Summary - TradingView
TransMedics Group, Inc. Quarterly Earnings Report - Stock Titan
TransMedics Group posts Q2 2026 revenue $189.9M, net income $14.7M; raises FY26 revenue guide - TradingView
TransMedics raises low end of 2026 revenue guidance to $737M - Stock Titan
Transmedics Group Inc Stock (TMDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Transmedics Group Inc Stock (TMDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gunderson Thomas J. | Director |
Jun 15 '26 |
Sale |
75.06 |
9,624 |
722,377 |
16,642 |
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):